Bausch & Lomb, has acquired the commercial assets of Italian ophthalmic pharmaceuticals business, Tubilux Pharma S.p.A, which markets proprietary, over-the-counter and branded generic products.
Bausch & Lomb, has acquired the commercial assets of Italian ophthalmic pharmaceuticals business, Tubilux Pharma S.p.A, which markets proprietary, over-the-counter and branded generic products. Its portfolio includes products for dry eye relief (Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).
This agreement more than doubles our presence in the Italian ophthalmic pharmaceuticals market, said Charl van Zyl, head of Bausch & Lomb's Pharmaceuticals business for Europe, Middle East and Africa. Bausch & Lomb is committed to expanding our portfolio offerings, and we believe that this investment will prove successful for the company, doctors and patients alike.
Financial terms of the agreement were not disclosed.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.